4.4 Article

Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants

Journal

DIGESTIVE DISEASES AND SCIENCES
Volume 66, Issue 10, Pages 3476-3481

Publisher

SPRINGER
DOI: 10.1007/s10620-020-06665-w

Keywords

Peptic ulcer disease (PUD); Non-steroidal anti-inflammatory drugs (NSAIDs); Proton-pump inhibitors (PPIs); Prophylaxis; Elderly; Antiplatelets; Anticoagulants

Ask authors/readers for more resources

PUD prophylaxis may be underused in elderly patients, especially in those receiving NSAID treatment and using antiplatelets and anticoagulants. Efforts are needed to raise physician awareness of PUD prophylaxis guidelines.
IntroductionPeptic ulcer disease (PUD) develops in approximately 25% of chronic users of non-steroidal anti-inflammatory drugs (NSAIDs). The incidence of uncomplicated PUD has been declining over the past 3 decades unlike that of complicated PUD in the elderly. An expert consensus document published jointly in 2008 by the American College of Gastroenterology (ACG), the American College of Cardiology Foundation (ACCF), and the American Heart Association (AHA) provided recommendations on prevention of PUD among users of antiplatelets and anticoagulants. This work aimed to evaluate physicians' compliance with these guidelines in a tertiary academic setting.MethodsWe examined our medical record database for the 9 month period extending from April 2018 until December 2018. Using this database, we identified elderly patients (>64 years old) who were chronic (>3 months) users of low dose aspirin (81 mg once daily) and had an indication for PUD prophylaxis as per the ACG-ACCF-AHA guideline document. We performed a retrospective chart review of patients included in this study. Descriptive statistics were compared using chi (2) and independent sample t tests.ResultsA total of 852 patients were included in this study. The mean age was 75 years old, and 43% of patients were females. In addition to aspirin, patients were prescribed P2Y12 inhibitors (45.5%), direct oral anticoagulants (DOACs) (23%), warfarin (12%), steroids (9%) or enoxaparin (1%). Users of DOACs were most commonly prescribed apixaban (16%), followed by rivaroxaban (6%) and dabigatran (1%). Overall, only 40% of patients with an indication for PUD prophylaxis received a proton pump inhibitor.ConclusionPUD prophylaxis may be underutilized in elderly patients. This finding, along with increasing rates of NSAID use and an aging population, may help explain the increased incidence of complicated PUD in the elderly. Efforts are needed to raise physician awareness of PUD prophylaxis guidelines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available